Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| Net loss | $(505,606) | $(413,840) | $(259,336) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Stock-based compensation | 55,724 | 49,487 | 41,116 |
| Depreciation on property and equipment | 409 | 377 | 231 |
| Non-cash lease expense | 99 | 133 | 1,130 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | 986 | 3,232 | (4,577) |
| Prepaid expenses and other current assets | 8,844 | (26,990) | 1,558 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s D&A?
- Immunovant, Inc. (IMVT) reported D&A of $96K in Q1 2026.
- How has Immunovant, Inc.'s D&A changed year-over-year?
- Immunovant, Inc.'s D&A decreased by 11.9% year-over-year, from $109K to $96K.
- What is the long-term trend for Immunovant, Inc.'s D&A?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s D&A has grown at a 34.2% compound annual growth rate (CAGR), from $126K to $409K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Immunovant, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude